HebeCell will attend the ISSCR 2019 International Symposium – “From Stem Cell Biology to New Therapies” from November 6-8, 2019 in Toronto, Canada.
HebeCell was founded in 2016 by a group of scientists with the focuses on Regenerative Medicine and Immuno-Oncology. Hebecell’s missions are: 1) To develop and commercialize cell-based therapeutics for incurable diseases; 2) To further explore and transform the infinite potentials of pluripotent stem cells into best-in-class products for the health of human beings. Hebecell operates a fully-equipped, state-of-the-art laboratory in Natick, MA. “
As our understanding of stem cell biology surges forward, new investigational therapies are rapidly advancing towards and through clinical trials. This special Toronto event “From Stem Cell Biology to New Therapies” will highlight current clinical applications of stem cell therapies. The program features world-renowned leaders in translational research from academia and industry, and will include an interactive panel that will discuss the regulatory challenges of translational stem cell research.
Hebecell will present two posters focusing on Immuno-oncology and regenerative medicine in this scientific symposium.
Poster 501
Title: Scalable Manufacture Platform of Human iPS-NK Cells for Immunotherapies
Presenter: Allen Feng, Ph.D., Chief Scientific Office
Date and Time: Thursday, November 7, 2019, 5:00pm – 6:00pm
Poster 611
Title: Generation of Photoreceptor Progenitors from Human Pluripotent Stem Cells Using a Scalable 3D Sphere Culture System.
Presenter: John Lu, Ph.D., CEO and President
Date and Time: Thursday, November 7, 2019, 5:00pm – 6:00pm